Product Description
For Dry Eye Syndrome
Mechanisms of Action: Type 2 Collagen Stimulant
Novel Mechanism: Yes
Modality: Unknown
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Laboratorios Sophia S.A de C.V.
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 4: Dry Eye Syndromes|Keratoconjunctivitis Sicca
Phase 1: Dry Eye Syndromes|Environmental Hypersensitivity|Keratoconjunctivitis Sicca
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT03524157 |
PRO-087/I | P1 |
Completed |
Dry Eye Syndromes|Keratoconjunctivitis Sicca|Environmental Hypersensitivity |
2018-02-12 |
2019-03-22 |
Treatments |
|
NCT04702776 |
PRO-087 | P4 |
Completed |
Dry Eye Syndromes|Keratoconjunctivitis Sicca |
2023-05-15 |
2024-01-06 |
Primary Completion Date|Primary Endpoints|Study Completion Date |
|
NCT03223909 |
087LATAMFIV | P4 |
Completed |
Dry Eye Syndromes|Keratoconjunctivitis Sicca |
2018-10-16 |
2019-11-01 |
Recent News Events
Date |
Type |
Title |
|---|